ELV vs PEN
Elevance Health vs Penumbra, Inc. — AI-powered side-by-side comparison
ELV
Elevance Health
69
Buy
VS
PEN
Penumbra, Inc.
71
Buy
| Metric | ELV | PEN |
|---|
| AI Score |
69
|
71
|
| Price |
$400.25
|
$327.06
|
| P/E Ratio |
17.79×
|
79.96×
|
| ROE |
12.9%
|
12.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
39.0%
|
67.8%
|
| Debt / Equity |
0.69×
|
0.14×
|
| Dividend Yield |
1.7%
|
0.0%
|
| RSI (14) |
62.8
|
82.9
|
| Beta |
0.692
|
0.701
|
| Expected Upside |
+0.5%
|
+6.0%
|
AI Committee View
Current Innellis committee reasoning for ELV versus PEN.
PEN leads by 2 points.
PEN scores 71/100 (Buy) versus ELV at 69/100 (Buy).
ELV Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
PEN Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- 2 consecutive earnings misses -- execution concerns — Growth
- RSI at 83 is in overbought territory — Technical